Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids
NCT ID: NCT00709579
Last Updated: 2008-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
60 participants
INTERVENTIONAL
2008-06-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Selection of the patients :Number of subjects required 60 :
* 30 patients needing an oral corticotherapy
* 30 patients needing a topical corticotherapy
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two steps for each patient:
1. the first step lasting 3 months : assessment of changes in mechanisms involved in ACIC with the RV3391A cream (M0 à M3). At the beginning of the corticotherapy, each patient will apply RV3391A on anterior side of a forearm and the placebo on the other side (randomised) for 3 months.
Clinical exam and objective measurements will be realised.
This step will allow us to describe and compare the evolution of cutaneous atrophy's markers produced by glucocorticoïds markers between M0 and M3:
* between topical and oral corticotherapy
* between RV3391A and the placebo.
2. the second step, the cohort follow-up, leading off the end of the first step (M3 à M24) The period of the second step will depend on the progression of patient's disease and on the period of his medical follow-up. This period may lasting until the 24th month after the inclusion in the study.
The patients will not apply RV3391A and the placebo anymore. They will be followed-up in the CHU.Assessments of the cutaneous atrophy's markers produced by glucocorticoïds will be realised at M6, M12, M18 and M24 with non invasive methods (clinical scoring, imaging, extensometry) to exactly describe on a long-term period the evolution of the ACIC. The assessments on forearm having received the placebo will allow us to know natural history of skin atrophy induced by corticotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
Placebo
placebo
RV3391A
RV3391A
A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RV3391A
A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
Placebo
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged over 50 years
* first corticotherapy over 0.5 mg/kg/day
* expectable period with a corticotherapy over 10 mg/day more than 3 months
* having signed a written informed consent form
* registered with a social security or health insurance system
* Patients needing a topical corticotherapy:
* aged over 50 years
* topical corticotherapy with a high or very high potency corticoid over 10 g/day
* expectable period with a topical corticotherapy more than 3 months
* having signed a written informed consent form
* registered with a social security or health insurance system
Exclusion Criteria
* Cutaneous inflammation on the anterior side of the forearm
* Medical history of psychosis induced by corticotherapy
* Medical history of allergy to RV3391A product its and excipients.
* Medical history of allergy to mineral cream Avene SPF50 excipients.
* Medical history of allergy to latex, surgical tape, chlorhexidine, lidocaine or xylocaine
* Clotting disorder or anticoagulant intake
* Healing disorder
* Women who are not post-menopausal women
* Substitutive estrogenotherapy for less than 6 months
* Impossibility to be registered in the Volunteers National Register
* Inability to comply with requirements of the clinical monitoring program,
* Inability to personally sign the informed consent form
* Is deprived of his freedom by an administrative or judicial decision; or who is under guardianship or protective custody
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Paul Sabatier of Toulouse
OTHER
University Hospital, Geneva
OTHER
Centre Européen de Recherche sur la Peau,
UNKNOWN
Pierre Fabre BIOMETRIE
UNKNOWN
Pierre Fabre Dermo Cosmetique
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pierre Fabre Dermo Cosmetique
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurent Sailler, Professor
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire
Anne-Marie Schmitt, Doctor
Role: STUDY_DIRECTOR
Pierre Fabre Dermo Cosmetique
Carle Paul, Professor
Role: STUDY_DIRECTOR
Centre Hospitalier Universitaire
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hopitalier Universitaire de Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-A00675-48
Identifier Type: -
Identifier Source: secondary_id
MODULCORTICOATROPHIE
Identifier Type: -
Identifier Source: org_study_id